A vaccine meant to prevent dengue, triggering symptoms that looked like dengue itself
Uma conquista científica brasileira — a primeira vacina de dose única contra a dengue, desenvolvida inteiramente no país — encontrou uma pausa forçada quando autoridades de saúde identificaram um padrão preocupante de reações adversas graves entre os primeiros vacinados. O Amazonas suspendeu sua campanha em 8 de junho, seguindo orientação do Ministério da Saúde e da Anvisa, após 42 casos severos e duas mortes em investigação entre aproximadamente 500 mil doses aplicadas nacionalmente. É o momento em que a promessa da inovação se depara com a responsabilidade da vigilância — e o país aguarda, em compasso de espera, o que a ciência ainda tem a dizer.
- Duas mortes sob investigação e 42 reações graves com sintomas que imitam a própria dengue severa — dor abdominal intensa, vômitos persistentes e sangramentos — acenderam o sinal de alerta nas autoridades federais.
- O Amazonas havia aplicado 5.780 das 25.580 doses recebidas quando a suspensão chegou, carregando consigo 84 notificações de eventos adversos que ainda aguardam classificação definitiva.
- A campanha nacional, que havia vacinado cerca de 500 mil pessoas com a Butantan-DV desde seu início, foi paralisada em todos os estados enquanto o Ministério da Saúde busca ativamente eventos não reportados.
- 916 pessoas vacinadas nas últimas três semanas no Amazonas serão monitoradas por 21 dias, com orientação para observar febre, dor abdominal e outros sinais de alerta e buscar atendimento imediato.
- O Instituto Butantan descreveu a suspensão como preventiva — não um abandono da vacina, mas uma pausa para compreender o que ocorreu em um subconjunto pequeno, porém significativo, de casos.
O estado do Amazonas interrompeu sua campanha de vacinação contra a dengue na segunda-feira, 8 de junho, após o Ministério da Saúde e a Anvisa identificarem um padrão alarmante: 42 casos de reações adversas graves associados à vacina do Instituto Butantan, além de duas mortes em investigação. A medida foi precautória e rapidamente se estendeu a outros estados, paralisando o rollout nacional.
A Butantan-DV chegara ao Amazonas carregando um simbolismo considerável — primeira vacina de dose única contra a dengue no mundo e a primeira desenvolvida inteiramente no Brasil. O estado havia recebido 25.580 doses e aplicado 5.780 delas, principalmente em trabalhadores da atenção primária à saúde. Mas 84 notificações de eventos adversos suspeitos acompanharam essas aplicações, número suficiente para acionar protocolos de segurança na capital.
No cenário nacional, entre aproximadamente 500 mil vacinados, foram registrados 3.703 eventos adversos — 0,7% dos receptores. Desses, 42 apresentaram sinais de alerta com sintomas que mimetizavam dengue grave: dor abdominal intensa, vômitos persistentes e sangramentos. Três casos foram classificados como graves. As duas mortes permanecem sob investigação ativa.
Tatyana Amorim, diretora da Fundação de Vigilância em Saúde do Amazonas, esclareceu que nenhuma das mortes investigadas federalmente ocorreu no estado. A gestora de imunizações Angela Desirée anunciou que 916 pessoas vacinadas nas últimas três semanas seriam acompanhadas por coordenadores municipais durante 21 dias, com orientação para monitorar febre, dor abdominal e outros sinais de alerta.
O Instituto Butantan reafirmou confiança no desenho da vacina, descrevendo a suspensão como necessária para reavaliar a estratégia — não uma retirada, mas uma pausa. Para quem já havia sido vacinado, a mensagem era clara: permanecer vigilante, buscar atendimento diante de qualquer sintoma e manter contato com as autoridades locais de saúde. A campanha que começara com tanto otimismo aguarda agora o que a investigação científica ainda tem a revelar.
The state of Amazonas halted its dengue vaccination campaign on Monday, June 8th, after federal health authorities flagged a troubling pattern: forty-two cases of severe adverse reactions tied to the Butantan Institute's vaccine, along with two deaths now under investigation by Brazil's Health Ministry. The suspension came on directive from both the Ministry of Health and the National Health Surveillance Agency (Anvisa), a precautionary measure that would ripple across the country as other states paused their own rollouts.
The Butantan-DV vaccine had arrived in Amazonas with considerable promise. It was the world's first single-dose dengue immunization and the first developed entirely in Brazil, marking a significant achievement in the nation's pharmaceutical independence. The state had received 25,580 doses and administered 5,780 of them, primarily to primary health care workers. But alongside those injections came eighty-four reports of suspected adverse events—a number that, while small in percentage terms, triggered alarm bells in the capital.
Nationally, the picture was more severe. Among roughly 500,000 people vaccinated with the Butantan-DV since the campaign began earlier in the year, 3,703 adverse events were reported overall, representing 0.7 percent of recipients. Of those, forty-two cases displayed what health officials called "warning signs"—symptoms that mimicked severe dengue itself. Patients reported intense abdominal pain, persistent vomiting, and bleeding. Three cases were classified as grave. Two people had died, and their cases remained under active investigation.
Tatyana Amorim, the director of Amazonas's Foundation for Health Surveillance, emphasized that none of the deaths under federal investigation had been recorded in her state. The foundation had logged no fatalities among its vaccinated population, though she did not clarify whether any of the forty-two severe cases nationally originated in Amazonas. The state's own eighty-four reported events—a figure that included both mild and serious reactions—remained under review.
What happened next was methodical and measured. The suspension would remain in place until health authorities completed their safety analysis, a timeline that remained undefined. But the work of monitoring did not stop. Angela Desirée, the immunization manager for the state health foundation, announced that 916 people who had received the vaccine within the previous three weeks would be tracked by municipal immunization coordinators. These individuals were instructed to watch for fever, abdominal pain, vomiting, and other warning signs, with health services standing ready to intervene if symptoms emerged.
The Butantan Institute itself issued a statement pledging to follow the Health Ministry's and Anvisa's guidance, describing the suspension as preventive and necessary for reassessing the vaccination strategy. The framing was important: this was not a withdrawal of confidence in the vaccine's fundamental design, but rather a pause to understand what had gone wrong in a small but significant subset of cases.
Across Brazil, the message was the same. States and municipalities were instructed to stop administering doses while investigations proceeded. The Health Ministry launched an effort to contact all states, urging them to search actively for additional adverse events that might not yet have been reported. For those who had already been vaccinated, the guidance was clear: remain vigilant, seek medical attention if symptoms appeared, and maintain contact with local health authorities. The campaign that had begun with such optimism—a homegrown vaccine, a single dose, protection against a disease that kills thousands in Brazil each year—had encountered a wall. What lay on the other side of it remained to be seen.
Citações Notáveis
The suspension has a preventive character and will remain in effect until the conclusion of analyses conducted by health authorities.— Amazonas Foundation for Health Surveillance
The measure demonstrates the functioning of surveillance and monitoring systems responsible for continuously evaluating the safety of immunizers used in the country.— Amazonas Foundation for Health Surveillance
A Conversa do Hearth Outra perspectiva sobre a história
Why did Amazonas move so quickly to suspend when they hadn't recorded any deaths themselves?
Because the federal signal was unmistakable. Forty-two severe cases and two deaths nationally—that's not noise. Even if Amazonas's own data looked clean, they couldn't ignore what the Health Ministry was seeing across the whole country. It's the difference between your neighborhood being safe and a pattern emerging in the city.
What does it mean that the symptoms mimicked severe dengue itself?
That's the unsettling part. People got vaccinated to prevent dengue, and some ended up with symptoms that looked like the disease they were trying to avoid. It raises the question of whether the vaccine was triggering something in certain people—an immune response, a genetic factor, something we don't yet understand.
The state applied 5,780 doses but reported 84 adverse events. Isn't that actually a low rate?
Mathematically, yes—about 1.5 percent. But when you're talking about a vaccine given to healthy people as prevention, not treatment, even a small percentage of severe reactions matters. And forty-two of those cases nationally crossed into territory that looked genuinely dangerous.
What happens to the people who were vaccinated?
They're being monitored for three weeks. That's the window where adverse reactions typically show up. If symptoms appear, they get medical attention. It's not abandonment; it's active surveillance. But it's also a waiting period, and that's stressful for people who did the right thing and got vaccinated.
Does this kill the vaccine entirely, or is it really just paused?
Officially, it's paused. The Butantan Institute and the Health Ministry both used the word "preventive." But two deaths under investigation is a heavy thing to come back from. The vaccine might be salvageable—maybe it's a batch issue, maybe it's a specific population at risk—but trust, once shaken, takes time to rebuild.